Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Pancreatic Adenocarcinoma 1Malignant Solid Tumor 1Lymphoma, T-Cell 1Lymphoma 1

Interventions

fludarabine 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1dexamethasone acetate 1Tetrahydrouridine 1Surveys and Questionnaires 1Sugars 1Melphalan 1Loratadine 1Lenalidomide 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma, T-Cell × Decitabine × Clear all
NCT02846935 2019-01-07

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
7 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡